产品
编 号：F251249
分子式：C20H19ClF3N3O4
分子量：457.83
分子式：C20H19ClF3N3O4
分子量：457.83
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 2042347-69-1
产品详情
生物活性：
AZD9898 is an orally active leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II) inhibitor, with an IC50 of 0.28 nM. AZD9898 mitigates the GABA binding and hepatic toxicity signal. AZD9898 has the potential to treat asthma.
体内研究：
AZD9898 with the single dose of 100 mg/kg is well tolerated and no safety concerns are raised.Animal Model:Rat 6M/group.
Dosage:10 and 100 mg/kg (for Toxicology Study).
Administration:Sing oral dose.
Result:Showed no signs of testicular toxicity, and only adaptive changes in the liver due to cytochrome P450 induction which were not judged adverse, providing a 200 fold margin between the no adverse effect level and the predicted human exposure at the predicted therapeutic dose.
AZD9898 is an orally active leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II) inhibitor, with an IC50 of 0.28 nM. AZD9898 mitigates the GABA binding and hepatic toxicity signal. AZD9898 has the potential to treat asthma.
体内研究：
AZD9898 with the single dose of 100 mg/kg is well tolerated and no safety concerns are raised.Animal Model:Rat 6M/group.
Dosage:10 and 100 mg/kg (for Toxicology Study).
Administration:Sing oral dose.
Result:Showed no signs of testicular toxicity, and only adaptive changes in the liver due to cytochrome P450 induction which were not judged adverse, providing a 200 fold margin between the no adverse effect level and the predicted human exposure at the predicted therapeutic dose.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备